clearance), a patented, sensor-based therapy that enables infants to actively trigger their parent’s voice to accelerate brain development during the NICU stay. Supported by a $2.5M NIH grant, issued U.S. patents, and clinical studies showing improvement in early brain measures, smallTalk is defining a new category of infant-driven neurodevelopmental therapy. Our high margin, hardware-enabled SaaS model allows NICUs to easily integrate developmental care tools with high clinical impact and strong commercial scalability.